Catalyst Pharmaceuticals (CPRX) Shareholder Broadfin Capital Upped Holding; Birmingham Capital Management Co Has Cut Position in Goodyear Tire & Rubber Co Com (GT) by $576,640

May 18, 2018 - By Jacob Smith

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

Kevin Kotler increased its stake in Catalyst Pharmaceuticals Inc (CPRX) by 2.97% based on its latest 2017Q4 regulatory filing with the SEC. Broadfin Capital Llc bought 204,800 shares as the company’s stock declined 36.55% with the market. The hedge fund run by Kevin Kotler held 7.10M shares of the health care company at the end of 2017Q4, valued at $27.75 million, up from 6.89M at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Catalyst Pharmaceuticals Inc for a number of months, seems to be bullish on the $343.70 million market cap company. The stock increased 0.30% or $0.01 during the last trading session, reaching $3.35. About 123,614 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 24.38% since May 18, 2017 and is uptrending. It has outperformed by 12.83% the S&P500.

Birmingham Capital Management Co Inc decreased its stake in Goodyear Tire & Rubber Co Com (GT) by 9.15% based on its latest 2017Q4 regulatory filing with the SEC. Birmingham Capital Management Co Inc sold 18,020 shares as the company’s stock declined 18.63% with the market. The institutional investor held 178,875 shares of the automotive aftermarket company at the end of 2017Q4, valued at $5.78 million, down from 196,895 at the end of the previous reported quarter. Birmingham Capital Management Co Inc who had been investing in Goodyear Tire & Rubber Co Com for a number of months, seems to be less bullish one the $6.26B market cap company. The stock decreased 0.91% or $0.24 during the last trading session, reaching $26.08. About 374,948 shares traded. The Goodyear Tire & Rubber Company (NASDAQ:GT) has declined 25.73% since May 18, 2017 and is downtrending. It has underperformed by 37.28% the S&P500.

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 15 analyst reports since April 26, 2016 according to SRatingsIntel. PiperJaffray upgraded Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) rating on Wednesday, October 5. PiperJaffray has “Overweight” rating and $4 target. H.C. Wainwright maintained it with “Buy” rating and $600 target in Friday, August 11 report. The stock has “Buy” rating by SunTrust on Monday, November 27. The company was downgraded on Tuesday, April 26 by Piper Jaffray. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) earned “Buy” rating by SunTrust on Tuesday, October 31. Roth Capital maintained the shares of CPRX in report on Wednesday, November 1 with “Buy” rating. H.C. Wainwright maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on Friday, November 10 with “Buy” rating. The firm has “Buy” rating by SunTrust given on Friday, September 1. The rating was maintained by Piper Jaffray with “Buy” on Friday, December 1. Roth Capital maintained it with “Buy” rating and $4.7500 target in Thursday, August 10 report.

More news for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were recently published by: Globenewswire.com, which released: “Catalyst Pharmaceuticals Introduces New Corporate Website” on April 24, 2018. Seekingalpha.com‘s article titled: “Catalyst Pharmaceutical Partners’ (CPRX) CEO Patrick McEnany on Q1 2018 Results – Earnings Call Transcript” and published on May 10, 2018 is yet another important article.

Since April 3, 2018, it had 1 buying transaction, and 0 selling transactions for $45,800 activity.

Broadfin Capital Llc, which manages about $1.26 billion and $611.75 million US Long portfolio, decreased its stake in Ignyta Inc (NASDAQ:RXDX) by 344,283 shares to 1.15 million shares, valued at $30.71M in 2017Q4, according to the filing. It also reduced its holding in Endo Intl Plc (NASDAQ:ENDP) by 569,000 shares in the quarter, leaving it with 2.44M shares, and cut its stake in Nuvasive Inc (NASDAQ:NUVA).

Investors sentiment decreased to 1.97 in 2017 Q4. Its down 0.03, from 2 in 2017Q3. It dropped, as 11 investors sold CPRX shares while 19 reduced holdings. 34 funds opened positions while 25 raised stakes. 55.25 million shares or 59.14% more from 34.72 million shares in 2017Q3 were reported. Caxton owns 0.16% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 33,110 shares. Group One Trading Lp owns 1,574 shares for 0% of their portfolio. Millennium Mgmt Ltd Liability Corp holds 0.01% or 2.07M shares in its portfolio. Metropolitan Life Com stated it has 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). State Board Of Administration Of Florida Retirement Sys holds 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 20,000 shares. Principal Group stated it has 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Hightower Ltd Com reported 10,411 shares. Virtu Financial Ltd Liability Corp holds 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 16,764 shares. Moreover, Knott David M has 0.59% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 380,110 shares. Deutsche Retail Bank Ag holds 0% or 662,502 shares. Stratos Wealth Prtn Ltd accumulated 0% or 1,500 shares. Great Point Ptnrs Lc accumulated 3.82M shares or 2.55% of the stock. Tiaa Cref Limited Co stated it has 183,487 shares. Bnp Paribas Arbitrage reported 14,857 shares or 0% of all its holdings. Hbk Sorce Advisory Ltd Liability holds 0.01% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) or 21,109 shares.

Analysts await The Goodyear Tire & Rubber Company (NASDAQ:GT) to report earnings on July, 27. They expect $0.74 EPS, up 5.71% or $0.04 from last year’s $0.7 per share. GT’s profit will be $177.48M for 8.81 P/E if the $0.74 EPS becomes a reality. After $0.50 actual EPS reported by The Goodyear Tire & Rubber Company for the previous quarter, Wall Street now forecasts 48.00% EPS growth.

Among 13 analysts covering Goodyear Tire (NASDAQ:GT), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Goodyear Tire had 37 analyst reports since October 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, July 28 by Morgan Stanley. The stock of The Goodyear Tire & Rubber Company (NASDAQ:GT) earned “Hold” rating by Standpoint Research on Wednesday, October 28. The stock of The Goodyear Tire & Rubber Company (NASDAQ:GT) earned “Buy” rating by Argus Research on Tuesday, November 10. The stock of The Goodyear Tire & Rubber Company (NASDAQ:GT) has “Hold” rating given on Wednesday, March 30 by Standpoint Research. As per Tuesday, November 22, the company rating was initiated by Berenberg. The stock of The Goodyear Tire & Rubber Company (NASDAQ:GT) earned “Hold” rating by Goldman Sachs on Tuesday, August 1. The firm has “Neutral” rating by Citigroup given on Monday, October 30. Jefferies downgraded the stock to “Hold” rating in Friday, February 24 report. Jefferies maintained it with “Buy” rating and $36.0 target in Tuesday, December 19 report. KeyBanc Capital Markets upgraded The Goodyear Tire & Rubber Company (NASDAQ:GT) on Thursday, April 7 to “Overweight” rating.

The Goodyear Tire & Rubber Company (NASDAQ:GT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>